Review of incretin-based therapy advancements covers dual/triple agonists, oral formulations, and combination strategies with discussion of challenges and future research directions.
Key findingReview of incretin-based therapy advancements covers dual/triple agonists, oral formulations, and co
What the researchers found
Review of incretin-based therapy advancements covers dual/triple agonists, oral formulations, and combination strategies with discussion of challenges and future research directions.
Why it matters
Relevant to the expanding applications of peptide-based therapies in medicine.
The numbers in context
Review covers multiple drug generations — from first GLP-1 drugs through dual (GIP/GLP-1) to triple (GIP/GLP-1/glucagon) agonists.
How the study worked
Study methodology detailed in the full publication.
Who was studied
Adults with type 2 diabetes across incretin therapy clinical trials
What this study cannot tell us
Limitations discussed in the full publication.
How to read the evidence
Evidence level based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to the growing body of evidence for peptide therapeutics across medical specialties.
Questions still open
- What are the long-term implications?
- How do results compare to existing evidence?
- What research is needed next?
Common questions
What does this mean for patients?
How reliable is this?
Read the original research
Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management.
Journal of basic and clinical physiology and pharmacology, 36(2-3), 95-111
Citation
Alluri, Amruth A; Guntupalli, Yashaswi; Suvarna, Shruti Suresh; Prystupa, Yuliya; Khetan, Shrishti Prakash; Vejandla, Bharath; Babu Swathi, Naraginti Lenin. (2025). Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management.. Journal of basic and clinical physiology and pharmacology, 36(2-3), 95-111. https://doi.org/10.1515/jbcpp-2025-0031